Table of Contents PART 01: Executive summary PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Highlights PART 05: Pipeline analysis PART 06: Market landscape • Global myasthenia gravis drugs market • Five forces analysis PART 07: Market segmentation by therapy area • Anticholinesterases • Immunosuppressants • IVIg PART 08: Geographical segmentation • Myasthenia gravis drugs market in Americas • Myasthenia gravis drugs market in EMEA • Myasthenia gravis drugs market in APAC PART 09: Market drivers • Approval of novel monoclonal antibodies • High unmet medical need • Growing research activities for the better understanding and diagnosis of myasthenia gravis PART 10: Impact of drivers PART 11: Market challenges • Presence of substitutes • Limited availability of approved drugs • Lack of long-term commitment PART 12: Impact of drivers and challenges PART 13: Market trends • Emergence of new entrants • Growing strategic acquisitions • Potential treatment options PART 14: Vendor landscape • Competitive scenario PART 15: Key vendor analysis • Flamel Technologies • F. Hoffmann-La Roche • Grifols • Pfizer • Shire • Valeant Pharmaceuticals • Other prominent vendors PART 16: Appendix • List of abbreviations PART 17: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Key customer segments of global myasthenia gravis drugs market Exhibit 03: Factors affecting the adoption rates of myasthenia gravis drugs market Exhibit 04: Key pipeline candidates Exhibit 05: Global myasthenia gravis drugs market snapshot Exhibit 06: Analysis of global myasthenia gravis drugs market Exhibit 07: Global myasthenia gravis drugs market 2016-2021 ($ millions) Exhibit 08: Opportunity analysis of global myasthenia gravis drugs market Exhibit 09: Opportunity analysis in developed and emerging markets Exhibit 10: Five forces analysis Exhibit 11: Segmentation of global myasthenia gravis drugs market by therapy Exhibit 12: Segmentation of global myasthenia gravis drugs market based on geography 2016 and 2021 Exhibit 13: Global myasthenia gravis drugs market revenue by geography 2016-2021 ($ millions) Exhibit 14: Market scenario in Americas Exhibit 15: Myasthenia gravis drugs market in Americas 2016-2021 ($ millions) Exhibit 16: Market scenario in EMEA Exhibit 17: Myasthenia gravis drugs market in EMEA 2016-2021 ($ millions) Exhibit 18: Market scenario in APAC Exhibit 19: Myasthenia gravis drugs market in APAC 2016-2021 ($ millions) Exhibit 20: Key drivers and challenges in APAC Exhibit 21: Key pipeline monoclonal antibodies Exhibit 22: Incidence data for myasthenia gravis (annually) Exhibit 23: Impact of drivers Exhibit 24: Forcefield analysis of drivers and challenges Exhibit 25: Impact of drivers and challenges Exhibit 26: Key entrants in myasthenia gravis drugs market Exhibit 27: Key acquisitions and their impact Exhibit 28: Competitive structure analysis of global myasthenia gravis drugs market 2015 Exhibit 29: Competitive analysis of global myasthenia gravis drugs market Exhibit 30: Market penetration of various myasthenia gravis manufacturers 2015 Exhibit 31: Flamel Technologies: Key highlights Exhibit 32: Flamel Technologies: Strength assessment Exhibit 33: Flamel Technologies: Strategy assessment Exhibit 34: Flamel Technologies: Opportunity assessment Exhibit 35: F. Hoffmann-La Roche: Strength assessment Exhibit 36: F. Hoffmann-La Roche: Strategy assessment Exhibit 37: F. Hoffmann-La Roche: Opportunity assessment Exhibit 38: F. Hoffmann-La Roche: Year-over-year (YoY) growth and revenue of MabThera/Rituxan 2013-2015 ($ billions) Exhibit 39: F. Hoffmann-La Roche: Geographic segmentation of MabThera/Rituxan by revenue 2015 Exhibit 40: F. Hoffmann-La Roche: YoY growth and revenue of CellCept 2013-2015 ($ millions) Exhibit 41: Grifols: Key highlights Exhibit 42: Grifols: Strength assessment Exhibit 43: Grifols: Strategy assessment Exhibit 44: Grifols: Opportunity assessment Exhibit 45: Pfizer: Strength assessment Exhibit 46: Pfizer: Strategy assessment Exhibit 47: Pfizer: Opportunity assessment Exhibit 48: Pfizer: YoY and growth rate of Medrol 2013-2015 ($ millions) Exhibit 49: Shire: Key highlights Exhibit 50: Shire: Strength assessment Exhibit 51: Shire: Strategy assessment Exhibit 52: Shire: Opportunity assessment Exhibit 53: Valeant Pharmaceuticals: Strength assessment Exhibit 54: Valeant Pharmaceuticals: Strategy assessment Exhibit 55: Valeant Pharmaceuticals: Opportunity assessment

Flamel Technologies, F. Hoffmann-La Roche, Grifols, Pfizer, Shire, Valeant Pharmaceuticals, Alexion Pharmaceuticals, Catalyst Pharmaceuticals, CSL, Curavac, Cytokinetics, Galencia, GlaxoSmithKline, Lupin Pharmaceuticals, Mitsubishi Tanabe Pharma, Novartis.